Skip to main content
Erschienen in: Basic Research in Cardiology 1/2011

01.01.2011 | Original Contribution

Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling

verfasst von: Nehmat Ghaboura, Sophie Tamareille, Pierre-Henri Ducluzeau, Linda Grimaud, Laurent Loufrani, Anne Croué, Yves Tourmen, Daniel Henrion, Alain Furber, Fabrice Prunier

Erschienen in: Basic Research in Cardiology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Recent studies reported cardioprotective effects of erythropoietin (EPO) against ischemia–reperfusion (I/R) injury through activation of the reperfusion injury salvage kinase (RISK) pathway. As RISK has been reported to be impaired in diabetes and insulin resistance syndrome, we examined whether EPO-induced cardioprotection was maintained in rat models of type 1 diabetes and insulin resistance syndrome. Isolated hearts were obtained from three rat cohorts: healthy controls, streptozotocin (STZ)-induced diabetes, and high-fat diet (HFD)-induced insulin resistance syndrome. All hearts underwent 25 min ischemia and 30 min or 120 min reperfusion. They were assigned to receive either no intervention or a single dose of EPO at the onset of reperfusion. In hearts from healthy controls, EPO decreased infarct size (14.36 ± 0.60 and 36.22 ± 4.20% of left ventricle in EPO-treated and untreated hearts, respectively, p < 0.05) and increased phosphorylated forms of Akt, ERK1/2, and their downstream target GSK-3β. In hearts from STZ-induced diabetic rats, EPO did not decrease infarct size (32.05 ± 2.38 and 31.88 ± 1.87% in EPO-treated and untreated diabetic rat hearts, respectively, NS) nor did it increase phosphorylation of Akt, ERK1/2, and GSK-3β. In contrast, in hearts from HFD-induced insulin resistance rats, EPO decreased infarct size (18.66 ± 1.99 and 34.62 ± 3.41% in EPO-treated and untreated HFD rat hearts, respectively, p < 0.05) and increased phosphorylation of Akt, ERK1/2, and GSK-3β. Administration of GSK-3β inhibitor SB216763 was cardioprotective in healthy and diabetic hearts. STZ-induced diabetes abolished EPO-induced cardioprotection against I/R injury through a disruption of upstream signaling of GSK-3β. In conclusion, direct inhibition of GSK-3β may provide an alternative strategy to protect diabetic hearts against I/R injury.
Literatur
1.
Zurück zum Zitat Amour J, Brzezinska AK, Jager Z, Sullivan C, Weihrauch D, Du J, Vladic N, Shi Y, Warltier DC, Pratt PF Jr, Kersten JR (2010) Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms. Anesthesiology 112:576–585CrossRefPubMed Amour J, Brzezinska AK, Jager Z, Sullivan C, Weihrauch D, Du J, Vladic N, Shi Y, Warltier DC, Pratt PF Jr, Kersten JR (2010) Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms. Anesthesiology 112:576–585CrossRefPubMed
2.
Zurück zum Zitat Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, Yellon DM (2008) Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 103:274–284CrossRefPubMed Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, Yellon DM (2008) Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 103:274–284CrossRefPubMed
3.
Zurück zum Zitat Bullard AJ, Govewalla P, Yellon DM (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100:397–403CrossRefPubMed Bullard AJ, Govewalla P, Yellon DM (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100:397–403CrossRefPubMed
4.
Zurück zum Zitat Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802–4806CrossRefPubMed Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802–4806CrossRefPubMed
5.
Zurück zum Zitat Ceylan-Isik A, Hunkar T, Asan E, Kaymaz F, Ari N, Soylemezoglu T, Renda N, Soncul H, Bali M, Karasu C (2007) Cod liver oil supplementation improves cardiovascular and metabolic abnormalities in streptozotocin diabetic rats. J Pharm Pharmacol 59:1629–1641CrossRefPubMed Ceylan-Isik A, Hunkar T, Asan E, Kaymaz F, Ari N, Soylemezoglu T, Renda N, Soncul H, Bali M, Karasu C (2007) Cod liver oil supplementation improves cardiovascular and metabolic abnormalities in streptozotocin diabetic rats. J Pharm Pharmacol 59:1629–1641CrossRefPubMed
6.
Zurück zum Zitat Dikow R, Wasserhess C, Zimmerer K, Kihm LP, Schaier M, Schwenger V, Hardt S, Tiefenbacher C, Katus H, Zeier M, Gross LM (2009) Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats. Basic Res Cardiol 104:571–579CrossRefPubMed Dikow R, Wasserhess C, Zimmerer K, Kihm LP, Schaier M, Schwenger V, Hardt S, Tiefenbacher C, Katus H, Zeier M, Gross LM (2009) Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats. Basic Res Cardiol 104:571–579CrossRefPubMed
7.
Zurück zum Zitat Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM (2001) The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes 50:455–461CrossRefPubMed Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM (2001) The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes 50:455–461CrossRefPubMed
8.
Zurück zum Zitat Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59:418–458CrossRefPubMed Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59:418–458CrossRefPubMed
9.
Zurück zum Zitat Flamment M, Gueguen N, Wetterwald C, Simard G, Malthiery Y, Ducluzeau PH (2009) Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat diet. Am J Physiol Endocrinol Metab 297:E1162–E1170CrossRef Flamment M, Gueguen N, Wetterwald C, Simard G, Malthiery Y, Ducluzeau PH (2009) Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat diet. Am J Physiol Endocrinol Metab 297:E1162–E1170CrossRef
10.
Zurück zum Zitat Gross ER, Hsu AK, Gross GJ (2007) Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 56:127–136CrossRefPubMed Gross ER, Hsu AK, Gross GJ (2007) Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 56:127–136CrossRefPubMed
11.
Zurück zum Zitat Guillard C, Chretien S, Pelus AS, Porteu F, Muller O, Mayeux P, Duprez V (2003) Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i)protein beta gamma-subunit-initiated pathway. J Biol Chem 278:11050–11056CrossRefPubMed Guillard C, Chretien S, Pelus AS, Porteu F, Muller O, Mayeux P, Duprez V (2003) Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i)protein beta gamma-subunit-initiated pathway. J Biol Chem 278:11050–11056CrossRefPubMed
12.
Zurück zum Zitat Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E (2005) Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 19:1323–1325PubMed Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E (2005) Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 19:1323–1325PubMed
13.
Zurück zum Zitat Hausenloy DJ, Tsang A, Yellon DM (2005) The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15:69–75CrossRefPubMed Hausenloy DJ, Tsang A, Yellon DM (2005) The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15:69–75CrossRefPubMed
14.
Zurück zum Zitat Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61:448–460CrossRefPubMed Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61:448–460CrossRefPubMed
15.
Zurück zum Zitat Heusch G (2009) No RISK, no…cardioprotection? A critical perspective. Cardiovasc Res 84:173–175CrossRefPubMed Heusch G (2009) No RISK, no…cardioprotection? A critical perspective. Cardiovasc Res 84:173–175CrossRefPubMed
16.
Zurück zum Zitat Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915–1919CrossRefPubMed Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915–1919CrossRefPubMed
17.
Zurück zum Zitat Joyeux-Faure M, Rossini E, Ribuot C, Faure P (2006) Fructose-fed rat hearts are protected against ischemia-reperfusion injury. Exp Biol Med (Maywood) 231:456–462 Joyeux-Faure M, Rossini E, Ribuot C, Faure P (2006) Fructose-fed rat hearts are protected against ischemia-reperfusion injury. Exp Biol Med (Maywood) 231:456–462
18.
Zurück zum Zitat Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535–1549PubMed Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535–1549PubMed
19.
Zurück zum Zitat Kaygisiz Z, Erkasap N, Yazihan N, Sayar K, Ataoglu H, Uyar R, Ikizler M (2006) Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts. J Physiol Sci 56:247–251CrossRefPubMed Kaygisiz Z, Erkasap N, Yazihan N, Sayar K, Ataoglu H, Uyar R, Ikizler M (2006) Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts. J Physiol Sci 56:247–251CrossRefPubMed
20.
Zurück zum Zitat Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, Kersten JR (2002) Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 96:183–188CrossRefPubMed Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, Kersten JR (2002) Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology 96:183–188CrossRefPubMed
21.
Zurück zum Zitat Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, Warltier DC (2001) Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 280:H1744–H1750PubMed Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, Warltier DC (2001) Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 280:H1744–H1750PubMed
22.
Zurück zum Zitat Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC (2000) Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 278:H1218–H1224PubMed Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC (2000) Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 278:H1218–H1224PubMed
23.
Zurück zum Zitat Kim HS, Cho JE, Hwang KC, Shim YH, Lee JH, Kwak YL (2010) Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival. Eur J Pharmacol 628:132–139CrossRefPubMed Kim HS, Cho JE, Hwang KC, Shim YH, Lee JH, Kwak YL (2010) Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival. Eur J Pharmacol 628:132–139CrossRefPubMed
24.
Zurück zum Zitat Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A (2004) Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47:1716–1721CrossRefPubMed Kristiansen SB, Lofgren B, Stottrup NB, Khatir D, Nielsen-Kudsk JE, Nielsen TT, Botker HE, Flyvbjerg A (2004) Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 47:1716–1721CrossRefPubMed
25.
Zurück zum Zitat Latifpour J, McNeill JH (1984) Cardiac autonomic receptors: effect of long-term experimental diabetes. J Pharmacol Exp Ther 230:242–249PubMed Latifpour J, McNeill JH (1984) Cardiac autonomic receptors: effect of long-term experimental diabetes. J Pharmacol Exp Ther 230:242–249PubMed
26.
Zurück zum Zitat Laviola L, Belsanti G, Davalli AM, Napoli R, Perrini S, Weir GC, Giorgino R, Giorgino F (2001) Effects of streptozocin diabetes and diabetes treatment by islet transplantation on in vivo insulin signaling in rat heart. Diabetes 50:2709–2720CrossRefPubMed Laviola L, Belsanti G, Davalli AM, Napoli R, Perrini S, Weir GC, Giorgino R, Giorgino F (2001) Effects of streptozocin diabetes and diabetes treatment by islet transplantation on in vivo insulin signaling in rat heart. Diabetes 50:2709–2720CrossRefPubMed
27.
Zurück zum Zitat Lim SY, Davidson SM, Yellon DM, Smith CC (2009) The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol 104:781–792CrossRefPubMed Lim SY, Davidson SM, Yellon DM, Smith CC (2009) The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol 104:781–792CrossRefPubMed
28.
Zurück zum Zitat Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2004) Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44:473–479CrossRefPubMed Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2004) Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44:473–479CrossRefPubMed
29.
Zurück zum Zitat Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW (1993) Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 88:1273–1278PubMed Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW (1993) Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 88:1273–1278PubMed
30.
Zurück zum Zitat Maddaford TG, Russell JC, Pierce GN (1997) Postischemic cardiac performance in the insulin-resistant JCR:LA-cp rat. Am J Physiol 273:H1187–H1192PubMed Maddaford TG, Russell JC, Pierce GN (1997) Postischemic cardiac performance in the insulin-resistant JCR:LA-cp rat. Am J Physiol 273:H1187–H1192PubMed
31.
Zurück zum Zitat Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, Terashima Y, Takada A, Ishikawa S, Shimamoto K (2009) ER stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-GSK-3{beta}-mediated suppression of mitochondrial permeability transition. Diabetes 58:2863–2872CrossRefPubMed Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, Terashima Y, Takada A, Ishikawa S, Shimamoto K (2009) ER stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-GSK-3{beta}-mediated suppression of mitochondrial permeability transition. Diabetes 58:2863–2872CrossRefPubMed
32.
Zurück zum Zitat Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349:1498–1504CrossRefPubMed Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349:1498–1504CrossRefPubMed
33.
Zurück zum Zitat Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y, Shimamoto K (2007) Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol 43:564–570CrossRefPubMed Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y, Shimamoto K (2007) Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol 43:564–570CrossRefPubMed
34.
Zurück zum Zitat Park SS, Zhao H, Mueller RA, Xu Z (2006) Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol 40:708–716CrossRefPubMed Park SS, Zhao H, Mueller RA, Xu Z (2006) Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol 40:708–716CrossRefPubMed
35.
Zurück zum Zitat Paulson DJ (1997) The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 34:104–112CrossRefPubMed Paulson DJ (1997) The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 34:104–112CrossRefPubMed
36.
Zurück zum Zitat Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ (2007) Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292:H522–H529CrossRefPubMed Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ (2007) Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292:H522–H529CrossRefPubMed
37.
Zurück zum Zitat Przyklenk K, Maynard M, Greiner DL, Whittaker P (2010) Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. doi:10.1089/ars.2010.3343 Przyklenk K, Maynard M, Greiner DL, Whittaker P (2010) Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. doi:10.​1089/​ars.​2010.​3343
38.
Zurück zum Zitat Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE (2005) Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 100:187–197CrossRefPubMed Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE (2005) Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 100:187–197CrossRefPubMed
39.
Zurück zum Zitat Raphael J, Gozal Y, Navot N, Zuo Z (2010) Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J Cardiovasc Pharmacol 55:348–357CrossRefPubMed Raphael J, Gozal Y, Navot N, Zuo Z (2010) Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J Cardiovasc Pharmacol 55:348–357CrossRefPubMed
40.
Zurück zum Zitat Ravingerova T, Stetka R, Volkovova K, Pancza D, Dzurba A, Ziegelhoffer A, Styk J (2000) Acute diabetes modulates response to ischemia in isolated rat heart. Mol Cell Biochem 210:143–151CrossRefPubMed Ravingerova T, Stetka R, Volkovova K, Pancza D, Dzurba A, Ziegelhoffer A, Styk J (2000) Acute diabetes modulates response to ischemia in isolated rat heart. Mol Cell Biochem 210:143–151CrossRefPubMed
41.
Zurück zum Zitat Riksen NP, Hausenloy DJ, Yellon DM (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29:258–267CrossRefPubMed Riksen NP, Hausenloy DJ, Yellon DM (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29:258–267CrossRefPubMed
42.
Zurück zum Zitat Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM (2005) Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol 289:H237–H242CrossRefPubMed Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM (2005) Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol 289:H237–H242CrossRefPubMed
43.
Zurück zum Zitat Sharma A, Singh M (2000) Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart. Pharmacol Res 41:635–640CrossRefPubMed Sharma A, Singh M (2000) Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart. Pharmacol Res 41:635–640CrossRefPubMed
44.
Zurück zum Zitat Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K (2002) Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 51:1110–1117CrossRefPubMed Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K (2002) Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 51:1110–1117CrossRefPubMed
45.
Zurück zum Zitat Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104:15–18CrossRefPubMed Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104:15–18CrossRefPubMed
46.
Zurück zum Zitat Tamareille S, Ghaboura N, Treguer F, Khachman D, Croue A, Henrion D, Furber A, Prunier F (2009) Myocardial reperfusion injury management: erythropoietin compared with postconditioning. Am J Physiol Heart Circ Physiol 297:H2035–H2043CrossRefPubMed Tamareille S, Ghaboura N, Treguer F, Khachman D, Croue A, Henrion D, Furber A, Prunier F (2009) Myocardial reperfusion injury management: erythropoietin compared with postconditioning. Am J Physiol Heart Circ Physiol 297:H2035–H2043CrossRefPubMed
47.
Zurück zum Zitat Tanaka K, Kehl F, Gu W, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR (2002) Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 282:H2018–H2023PubMed Tanaka K, Kehl F, Gu W, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR (2002) Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 282:H2018–H2023PubMed
48.
Zurück zum Zitat Thim T, Bentzon JF, Kristiansen SB, Simonsen U, Andersen HL, Wassermann K, Falk E (2006) Size of myocardial infarction induced by ischaemia/reperfusion is unaltered in rats with metabolic syndrome. Clin Sci (Lond) 110:665–671CrossRef Thim T, Bentzon JF, Kristiansen SB, Simonsen U, Andersen HL, Wassermann K, Falk E (2006) Size of myocardial infarction induced by ischaemia/reperfusion is unaltered in rats with metabolic syndrome. Clin Sci (Lond) 110:665–671CrossRef
49.
Zurück zum Zitat Tong H, Imahashi K, Steenbergen C, Murphy E (2002) Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90:377–379CrossRefPubMed Tong H, Imahashi K, Steenbergen C, Murphy E (2002) Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90:377–379CrossRefPubMed
50.
Zurück zum Zitat Tosaki A, Engelman DT, Engelman RM, Das DK (1996) The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 31:526–536PubMed Tosaki A, Engelman DT, Engelman RM, Das DK (1996) The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 31:526–536PubMed
51.
Zurück zum Zitat Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N (2003) Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308:990–994CrossRefPubMed Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N (2003) Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308:990–994CrossRefPubMed
52.
Zurück zum Zitat Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM (2005) Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54:2360–2364CrossRefPubMed Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM (2005) Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 54:2360–2364CrossRefPubMed
53.
Zurück zum Zitat Wagner C, Kloeting I, Strasser RH, Weinbrenner C (2008) Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 52:430–437CrossRefPubMed Wagner C, Kloeting I, Strasser RH, Weinbrenner C (2008) Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 52:430–437CrossRefPubMed
54.
Zurück zum Zitat Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO (2004) Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18:1031–1033PubMed Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO (2004) Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18:1031–1033PubMed
55.
Zurück zum Zitat Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, Theobald HA, Cooksey RC, Kandror KV, Abel ED (2009) Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res 82:351–360CrossRefPubMed Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, Theobald HA, Cooksey RC, Kandror KV, Abel ED (2009) Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res 82:351–360CrossRefPubMed
56.
Metadaten
Titel
Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling
verfasst von
Nehmat Ghaboura
Sophie Tamareille
Pierre-Henri Ducluzeau
Linda Grimaud
Laurent Loufrani
Anne Croué
Yves Tourmen
Daniel Henrion
Alain Furber
Fabrice Prunier
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Basic Research in Cardiology / Ausgabe 1/2011
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-010-0130-3

Weitere Artikel der Ausgabe 1/2011

Basic Research in Cardiology 1/2011 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.